
News|Articles|January 5, 2024
Determining the best approach for your Container Closure Integrity Testing needs
Author(s)Eurofins
Container-Closure Integrity (CCI) is essential for ensuring the stability and safety of drug products over time. The USP recommends deterministic methods over older probabilistic ones like dye ingress, emphasizing the need to assess the significance of leakage in relation to product quality. Eurofins can assist in choosing and validating appropriate CCI testing methods tailored to specific product and closure system configurations, as there is no one-size-fits-all solution outlined in the USP.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
Industry Outlook 2026: Trends Transitioning from 2025 into 2026
2
Medable Presents AI Agent for Automating Trial Master File Processes at JP Morgan Healthcare Conference
3
Amgen Acquires UK Biotech Dark Blue Therapeutics
4
Gene Therapy, Rare Diseases, and Transfer RNA
5